ang 2  (R&D Systems)

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: ANGPT2 expression in multiple tumors. (A) ANGPT2 levels in 18 human tumors using TCGA tumor and normal data. (B-H) ANGPT2 levels in TCGA; (B) CHOL, (C) ESCA, (D) GBM, (E) HNSC, (F) KICH, (G) KIRC and (H) STAD tissues vs. the matching TCGA and GTEx normal tissues. *P<0.05, **P<0.01 and ***P<0.001; all P-values are adjusted for multiple comparisons where applicable. ANGPT2, angiopoietin-2; TCGA, The Cancer Genome Atlas; CHOL, cholangiocarcinoma; ESCA, esophageal cancer; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; STAD, stomach adenocarcinoma.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: Gene expression profiling interactive analysis database: OS and DFS analysis of ANGPT2 in diverse human tumors. (A-G) OS plot: ANGPT2 in (A) CHOL, (B) ESCA, (C) GBM, (D) HNSC, (E) KICH, (F) KIRC and (G) STAD. (H-N) DFS plot: ANGPT2 in (H) CHOL, (I) ESCA, (J) GBM, (K) HNSC, (L) KICH, (M) KIRC and (N) STAD. OS, Overall survival; DFS, disease-free survival; ANGPT2, angiopoietin-2; CHOL, cholangiocarcinoma; ESCA, esophageal cancer; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; STAD, stomach adenocarcinoma.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Gene Expression

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: Association of ANGPT2 expression with clinical analysis in ESCA. (A-D) ANGPT2 expression in the GSE20347 , GSE38129 , GSE45670 and GSE70409 datasets. (E) Paired ANGPT2 expression in adjacent and tumor tissues. (F) Correlation between ANGPT2 expression and grade. (G) Impact of ANGPT2 expression on OS in patients with ESCA. (H) Multivariate Cox regression: Connection with OS and clinicopathologic characteristics in patients with ESCA. (I) Nomogram for the 1-, 3-, and 5-yr OS prediction of patients with ESCA. (J) Representative images and (K) statistical analysis: ANGPT2 expression in ESCA tumors and normal tissues. Scale bars, 50 µm. (K) Number of ANGPT2 expression negative or positive cases in normal tissues and ESCC tissues based on the IHC staining score results. The results demonstrated that 16 cases were negative and only 5 cases were positive for ANGPT2 expression in normal tissues, while merely 2 cases were negative and 19 cases were positive for ANGPT2 expression in ESCC tissues. (L) ANGPT2 protein expression in paired tissues obtained from patients with ESCA. (M) ANGPT2 mRNA expression levels in ESCA and paired adjacent normal tissues. (N) Kaplan-Meier: Prognosis of OS according to the IHC scores of ANGPT2. Statistical analyses: Paired Student's t-test was used for comparisons between paired tumor and normal tissues (E, L and M); unpaired Student's t-test was used for comparison of IHC scores between tumor and normal tissues (K); one-way ANOVA was used for analyzing ANGPT2 expression across different tumor grades (F); log-rank test was used for survival analyses (G and N); Cox proportional hazards model was used for multivariate regression analysis (H). *P<0.05 and **P<0.01; all P-values are adjusted for multiple comparisons where applicable. ANGPT2, angiopoietin-2; ESCA, esophageal cancer; OS, overall survival; ESCC, esophageal squamous cell carcinoma; IHC, immunohistochemical.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing, Immunohistochemistry, Comparison, Immunohistochemical staining

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: Upstream regulator of ANGPT2 in ESCA. (A) Cytoscape software: miRNA-ANGPT2 regulatory network. (B) Expression correlation between predicted miRNAs and ANGPT2 in ESCA. (C) Unsupervised hierarchical clustering heatmap based on the differentially expressed miRNAs between 185 ESCA tissues and 13 healthy tissues. (D) miR-145-5p level in ESCA and control normal samples. (E) Collation analysis: miR-145-5p and AMPKAPK5-AS1, as well as (F) miR-145-5p and SNHG1. (G) AMPKAPK5-AS1 and (H) SNHG1 expression levels in adjacent and tumor tissues. (I) Overall survival analysis: AMPKAPK5-AS1 and (J) SNHG1 in patients with ESCA. Statistical analyses: Unpaired Student's t-test was used for comparing lncRNA/miRNA expression levels between tumor and normal tissues (D, G and H); Spearman's rank correlation coefficient was used for evaluating correlations between gene expression levels (B, E and F); log-rank test was used for survival analyses (I and J). All P-values were adjusted for multiple comparisons using the Benjamini-Hochberg method to control the false discovery rate. All P-values are adjusted for multiple comparisons where applicable. ANGPT2, angiopoietin-2; ESCA, esophageal cancer; miRNAs or miRs, microRNAs.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Software, Expressing, Control, Gene Expression

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: Connection of ANGPT2 expression with immunity in ESCA. (A) GSEA enrichment plots showing signaling pathways significantly enriched in the ANGPT2 high-expression group (1,000 permutations were performed; pathways include ‘ALLOGRAFT_REJECTION’ and ‘INTERFERON_GAMMA_RESPONSE’, consistent with immune-related functions). (B-H) Spearman's correlation analysis between ANGPT2 expression and infiltration levels of specific immune cell subsets in ESCA (adjusted for tumor purity via TIMER2.0 or indicated algorithms): (B) CD8 + T cells (TIMER, Rho=0.220, P=2.04×10 −3 ); (C) myeloid dendritic cells (TIMER, Rho=0.286, P=9.76×10 −5 ); (D) macrophages (EPIC, Rho=0.211, P=2.87×10 −3 ); (E) macrophage/monocytes (MCPCOUNTER, Rho=0.178, P=1.67×10 −2 ), (F) neutrophils (TIMER, Rho=0.132, P=4.34×10 −2 ), (G) NK cells (EPIC, Rho=0.148, P=4.81×10 −2 ), (H) T follicular helper cells (CIBERSORT, Rho=0.260, P=3.68×10 −4 ). (I) Single-sample GSEA showing the abundance of 23 infiltrating immune cell subgroups in ANGPT2 high- vs. low-expression groups. (J) ESTIMATE algorithm analysis of Stromal Score, Immune Score and ESTIMATE Score in ANGPT2 high- vs. low-expression groups (P<0.01 for Stromal Score; P<0.05 for Immune Score; P<0.01 for ESTIMATE Score, as indicated by symbols). *P<0.05, **P<0.01 and ***P<0.001; all P-values are adjusted for multiple comparisons where applicable. ANGPT2, angiopoietin-2; ESCA, esophageal cancer; GSEA, Gene Set Enrichment Analysis; NK, natural killer.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing, Protein-Protein interactions

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: Relation of ANGPT2 level with immune checkpoint and chemotherapeutic sensitivity in ESCA. (A) TIMER-conducted Spearman correlation: ANGPT2 with CTLA-4 expression in ESCA. (B) TCGA-determined expression correlation: ANGPT2 with CTLA4 in ESCA. (C) TIMER-conducted Spearman correlation: ANGPT2 with HAVCR2 expression in ESCA. (D) TCGA-determined expression correlation: ANGPT2 with HAVCR2 in ESCA. (E) TIMER-conducted Spearman correlation: ANGPT2 with PDCD1LG2 expression in ESCA. All TIMER-conducted Spearman correlations were adjusted by purity. (F) TCGA-determined expression correlation: ANGPT2 with PDCD1LG2 in ESCA. (G-L) Relationships between both ANGPT2 expression groups and chemotherapeutic sensitivity. ANGPT2, angiopoietin-2; ESCA, esophageal cancer; TCGA, The Cancer Genome Atlas.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing

Journal: Genes to Cells

Article Title: Attenuation of Oxygen‐Induced Neovascularization and Inflammation by Neutralizing VEGFA and/or ANG ‐2 With an Antibody

doi: 10.1111/gtc.70107

Figure Lengend Snippet: Effects of anti‐VEGFA, ‐ANG‐2, or bispecific antibody on pathological neovascularization in the mouse OIR model. (A) Schematic representation of the experimental design to evaluate the effects of intraocular injected antibodies in a mouse OIR model. The antibodies were intravitreally injected into OIR mice at P14. Retinal whole‐mounts were prepared at P17 and P19 and immunostained with anti‐CD31 antibody. (B) The areas of neovascularization (red) and vaso‐obliteration (non‐perfusion, yellow) in the OIR retina treated with control IgG, anti‐VEGFA antibody, anti‐ANG‐2 antibody, or anti‐VEGFA/ANG‐2 bispecific antibody are shown. Scale bar = 1 mm. (C and D) The area (% of total area) of neovascularization and the vaso‐obliteration area in the OIR mouse retina. The averages of the area with standard errors are shown in the bar graphs. (E and F) The antibodies were intravitreally injected into OIR mice at P14, and the retina was harvested at P17 and frozen sectioned. Immunostaining with anti‐CD31 and ‐Ki67 antibodies was performed to examine endothelial cell proliferation. Scale bar = 50 μm. Nuclei were visualized with DAPI staining. Numbers of CD31 and Ki67 double‐positive cells inner to the INL were counted (F). Data are the averages of 8 samples with standard deviation. (C, D, F) Tukey's HSD test was used for the statistical analysis. * p < 0.05; ** p < 0.01.

Article Snippet: Recombinant VEGFA (Thermo Fisher Scientific, 450‐32) and ANG‐2 (R&D SYSTEMS, 7186‐AN‐025) were labeled with Alexa Fluor 488 using a Microscale Protein Labeling Kit (Thermo Fisher Scientific, A30006).

Techniques: Injection, Control, Immunostaining, Staining, Standard Deviation

Journal: Genes to Cells

Article Title: Attenuation of Oxygen‐Induced Neovascularization and Inflammation by Neutralizing VEGFA and/or ANG ‐2 With an Antibody

doi: 10.1111/gtc.70107

Figure Lengend Snippet: Gene expression patterns of the OIR retina administered antibodies at P17 and P19. RNAseq was performed using whole RNA purified from the retinas of normal mice and OIR mice administered the antibodies. Four samples of each condition were prepared. (A) Volcano plots are shown. Upregulated genes (≥ log2 (1.5)) are indicated as red circles, and downregulated genes (≤ − log2 (1.5)) are indicated as blue circles. (B–E) TPM values of specific genes are shown. A2, ANG‐2 antibody; C, control; V, VEGFA antibody; VA2, Bispecific antibody. Tukey's HSD test was used for the statistical analysis. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Recombinant VEGFA (Thermo Fisher Scientific, 450‐32) and ANG‐2 (R&D SYSTEMS, 7186‐AN‐025) were labeled with Alexa Fluor 488 using a Microscale Protein Labeling Kit (Thermo Fisher Scientific, A30006).

Techniques: Gene Expression, RNA sequencing, Purification, Control

Journal: Genes to Cells

Article Title: Attenuation of Oxygen‐Induced Neovascularization and Inflammation by Neutralizing VEGFA and/or ANG ‐2 With an Antibody

doi: 10.1111/gtc.70107

Figure Lengend Snippet: Changes of IBA1‐positive cells and the effects of intraocular injected anti‐VEGFA, ‐ANG‐2, or bispecific antibody. (A) Retinal whole‐mounts of the OIR mice at P17 and P19 treated with control IgG, anti‐VEGFA, ‐ANG‐2, or bispecific antibody were immunostained with anti‐IBA1 antibody and observed by a confocal microscope. Scale bar = 1 mm. (B) The IBA1 signal‐positive area was examined using ImageJ software, and the percentage of the positive area to the whole area is shown in (B). The averages of 3 independent samples with standard deviation are shown. * p < 0.05; ** p < 0.01. (C) Alexa Fluor (AF) 488‐conjugated VEGFA or ANG‐2 was intravitreally injected into OIR mice at P17. The eyes were harvested one hour after the injection, and whole‐mounts were immunostained with anti‐CD31 and anti‐IBA1 antibodies and observed by a confocal microscope. White arrowheads indicate VEGFA‐ or ANG‐2‐Alexa Fluor 488 signals in IBA1‐positive cells. Scale bar = 20 μm.

Article Snippet: Recombinant VEGFA (Thermo Fisher Scientific, 450‐32) and ANG‐2 (R&D SYSTEMS, 7186‐AN‐025) were labeled with Alexa Fluor 488 using a Microscale Protein Labeling Kit (Thermo Fisher Scientific, A30006).

Techniques: Injection, Control, Microscopy, Software, Standard Deviation

Journal: bioRxiv

Article Title: Splenic tropism of Plasmodium vivax in acute infection and spleen-attenuated systemic inflammation

doi: 10.64898/2026.03.25.714340

Figure Lengend Snippet: Comparison of plasma concentrations of A) CFHb, B) IL-6, C) TNF-alpha, D) ang-2, E) IL1-beta, F) IL-18 and G) IL-10 in spleen-intact (spleen) and splenectomized individuals (No spleen, n=25) with acute uncomplicated vivax malaria in Timika, Indonesia. Data points are individual patients with median and interquartile range shown. All measurements in the spleen-intact group were from cohort 1 (n=24), except CFHb (cohort 2, n=36). Measurements below the detection limit of each marker were assigned a value of half the lower limit of detection of the assay, comprising of the following number of patients: 3 TNF-alpha and 2 IL-10 in the spleen-intact group, and 2 TNF-alpha, 7 IL-1b, 1 IL-18 and 2 IL-10 in the splenectomized group. The Mann-Whitney U test was used for statistical comparison. Abbreviations: CFHb, cell-free hemoglobin; IL-6, interleukin-6, TNF-alpha, tumour necrosis factor-alpha; ang-2, angiopoietin-2; IL-1b, interleukin-1 beta; IL-18, interleukin-18; IL-10, interleukin-10.

Article Snippet: Plasma levels of the endothelial activation marker, angiopoietin-2 (ang-2), and the pro-inflammatory cytokine, interleukin-6 (IL-6), were determined using the QuantikineTM ELISA Human Ang-2 and Human IL-6 Immunoassays from R&D Systems (Bio-Techne, US).

Techniques: Comparison, Clinical Proteomics, Marker, MANN-WHITNEY